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The PAX6 gene is involved in ocular morphogenesis and is expressed in the developing central nervous system and
numerous ocular tissues during development. PAX6 mutations have been detected in various ocular anomalies,
including aniridia, Peters anomaly, corneal dystrophy, congenital cataracts, and foveal hypoplasia. However, it has
not been identified in patients with optic-nerve malformations. Here, we identified novel mutations in eight pedigrees
with optic-nerve malformations, including coloboma, morning glory disc anomaly, optic-nerve hypoplasia/aplasia,
and persistent hyperplastic primary vitreous. A functional assay demonstrated that each mutation decreased the
transcriptional activation potential of PAX6 through the paired DNA-binding domain. PAX6 and PAX2 are each
thought to downregulate the expression of the other. Four of the detected mutations affected PAX6-mediated
transcriptional repression of the PAX2 promoter in a reporter assay. Because PAX2 gene mutations were detected
in papillorenal syndrome, alternation of PAX2 function by PAX6 mutations may affect phenotypic manifestations
of optic-nerve malformations.
Previous ophthalmoscopy and medical imaging studies
have established a variety of clinical entities in optic-nerve
malformation (Brown and Tasman 1983), since numer-
ous tissues and developmental events contribute to the
optic-nerve architecture. The optic nerve first arises as
the optic stalk between the forebrain and optic vesicle
at 3 wk human gestation. At 5–6 wk, mesenchymes and
vessels invade through the embryonic fissure, a tran-
siently appearing ventral cleft of the optic stalk and optic
cup, into the vitreous cavity. Nerve fibers of retinal gan-
glion cells then begin to project into the CNS at 8–10
wk. In the middle stage, the optic nerve is coated with
a collagen sheath and propped up by glial cells, and the
nerve head is transiently covered with glial cells and hy-
aloid vessels. In this series of events, developmental fail-
ure of the embryonic fissure (resulting in coloboma), ret-
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inal ganglion cells (optic-nerve hypoplasia/aplasia), and
hyaloid vessels (persistent hyperplastic primary vitreous)
cause disease (Brown and Tasman 1983). Most of these
anomalies are sporadic, but autosomal dominant inher-
itance has been reported in families with coloboma of
the optic nerve (CON [MIM 120430]) and optic-nerve
hypoplasia (ONH [MIM 165550]). Mutations causing
autosomal dominant syndrome have been identified in
two transcription factor genes. The PAX2 gene, one of
nine known paired box genes, is expressed in the de-
veloping optic stalk, the ventral half of the optic cup,
and the kidney, and its mutations cause papillorenal syn-
drome (PRS [MIM 120330]) (Sanyanusin et al. 1995).
HESX1 gene mutations, expressed in the ventral half of
the forebrain, Ratke’s pouch, and pituitary gland, were
identified in patients with septo-optic dysplasia (SOD
[MIM 182230]) (Dattani et al. 1998). However, there
has not been genetic interpretation of various manifes-
tations of optic-nerve malformations.
The Pax6/PAX6 gene, first isolated as a candidate gene
for human aniridia and expressed in developing CNS and
various ocular tissues (Walther and Gruss 1991; Nishina
et al. 1999), encodes a transcription factor that is involved
in eye morphogenesis (Gehring 1996). Genetic analysis
1566 Am. J. Hum. Genet. 72:1565–1570, 2003
has detected numerous PAX6 mutations, not only in
patients with aniridia but also with other eye anomalies
(summarized in the Human PAX6 Mutation Database).
In situ hybridization and immunohistochemistry indi-
cated PAX6 expression in the developing optic nerve
(Walther and Gruss 1991; Nishina et al. 1999), and the
small eye (SeyH) mouse mutant with a deletion of the
Pax6 locus showed coloboma, a defect of the initial in-
vagination in the optic stalk and cup (Glaser et al. 1990).
However, there is no evidence of PAX6 mutations in pa-
tients with optic-nerve malformations.
We screened for PAX6 mutations in genomic DNA
from 155 individuals with a variety of congenital optic-
nerve malformations by use of PCR-SSCP analysis. PCR
primers used to amplify PAX6 exons were synthesized
on the basis of the reported sequence (Glaser et al. 1992);
the primer sequences can be found in appendix A (online
only), and the conditions of PCR and SSCP analyses were
described elsewhere (Azuma et al. 1999). Nucleotide se-
quences were determined directly or after cloning into
plasmid pUC18 by use of a Sequenase version 2 kit
(Amersham) with PCR primers or universal primers in
pUC18. Eight mutations were detected.
Patient 1, a 5-year-old girl, had bilateral morning glory
disc anomaly. Mutation analysis identified 619CrT nu-
cleotide substitution (according to GenBank accession
number M93650), which is expected to result in P68S
(fig. 1a). Patient 2, a 21-year-old male, had bilateralONH
and 1030CrT (Q205X) (fig. 1b). Patient 3, a 1-year-
old boy, had an iris anomaly, large coloboma of the optic
nerve, retina, and choroids, a remnant of hyaloid vessel
proliferation (persistent hyperplastic primary vitreous)
bilaterally, and growth andmental retardation;mutation
analysis identified 1190TrC (F258S) (fig. 1c). Patient 4,
a 2-year-old boy, had bilateral ONH, growth andmental
retardation, an enlarged ventricle by computed tomog-
raphy (CT) study, multiple spike and wave bursts by
electroencephalogram, and vesicoureteral reflux; muta-
tion analysis identified 1292GrT (S292I) (fig. 1d). Pa-
tient 5, a 1-year-old girl, had Peters anomaly in the left
eye and slight corneal opacity, deep excavation of the
optic-nerve head in the right eye, and 1504TrC (S363P)
(fig. 1e). Patient 6, a 2-mo-old girl, had microphthalmos
in the right eye, iris dysplasia and optic-nerve aplasia
with a remnant of the hyaloid vessels in the left eye, and
1550ArG (Q378R) (fig. 1f). Patient 7, a 19-year-old
male, had bilateral ONH and 1558ArG (M381V) (fig.
1g). Patient 8, a 4-mo-old girl, had bilateral optic-nerve
aplasia and 1588ArG (T391A) (fig. 1h). Further clinical
details can be found in appendix A (online only).
All patients except patients 3 and 4 had normal growth,
intelligence, results of physical examination, and appear-
ance on CT. Each had a normal karyotype. The muta-
tions detected here occurred on one of the alleles (were
thus heterozygous) and were not detected in unaffected
immediate family members or in 1100 normal individu-
als, indicating sporadic occurrence. Since mutations of
the PAX2 gene were detected in patients with optic-nerve
anomalies associated with renal anomaly (PRS) (Sanyanu-
sin et al. 1995), we screened for PAX2 but failed to detect
any mutation in these patients (data not shown).
Although all the mutations are indicated to be spo-
radic, each occurred in an important amino acid residue,
which suggests that they cause disease. Seven of the eight
mutations were missense, one of which was positioned
in the paired domain (PD), one in the homeodomain
(HD), and five in the proline-serine-threonine-rich trans-
activating domain (PST). The proline residue at 68 in the
PD and the phenylalanine residue at 258 in the HD are
conserved throughout all Pax family members identified
to date. The serine residues at 292 and 363, the glu-
tamine residue at 378, the methionine residue at 381,
and the threonine residue at 391 in the PST are con-
served throughout all the vertebrate Pax6 homologues
identified to date. Amino acid sequences of the PST are
conserved in vertebrates but considerably diversified in
invertebrates.
We next performed functional assay of the mutations.
The mutant forms of PAX6 cDNAs, generated by PCR-
based in vitro mutagenesis, were cloned into plasmids
pBluescript and pCAGGS, the latter of which contains a
cytomegalovirus enhancer and chicken b-actin promoter
(Yamaguchi et al. 1997; Azuma et al. 1999). Wild-type
and mutant forms of PAX6 proteins were synthesized
by in vitro transcription and translation by use of rabbit
reticulocyte lysate in the presence of [35S] methionine.
SDS-polyacrylamide gel electrophoresis and fluorography
of the reactions revealed that the PAX6 proteins with
expected molecular weights were produced at similar
efficiency (data not shown). It is, therefore, unlikely that
the mutations affect the efficiency of translation or sta-
bility of PAX6 protein.
To examine possible functional changes by the detected
mutations, we performed a chloramphenicol acetyltrans-
ferase (CAT) assay in mouse embryonic carcinoma P19
cells, which are often used for functional analysis of the
PAX6 gene. First, a CAT-reporter construct carrying six
copies of P6CON, the consensus binding sequence of the
PAX6 PD (Epstein et al. 1994; Yamaguchi et al. 1997),
was used. Wild-type PAX6 strongly activated CAT re-
porter-gene expression, and the transcriptional activa-
tion potential of PAX6 was more or less affected by all
the mutations reproducibly, with significant impairment
by P68S, Q205X, F258S, and S292I (fig. 2b). The mu-
tation within the HD (F258S) impaired the PD-mediated
transcriptional activation and is consistent with a report
of the functional interplay of the PD and theHD (Mishra
et al. 2002).
In the optic stalk and ventral forebrain of the zebrafish
embryo, Pax2 and Pax6 expression is inversely correlated
Figure 1 a, Fundus photography (panel 1) and fluorescein angiography (panel 2) of the right eye of patient 1, showing a morning glory
disc anomaly. The optic-nerve region is excavated, and white tissue is present at the bottom. Panel 3, Mutation analysis identified 619CrT in
exon 6 (P68S). b, Fundus photography (panel 1) and fluorescein angiography (panel 2) of the right eye of patient 2, showing a small optic-
nerve head surrounded by a hypopigmented ring. Panel 3, Mutation detection of 1030CrT in exon 8 (Q205X). c, Photographs showing the
anterior segments (panel 1 and panel 4) and fundus (panel 2, panel 3, and panel 5) of patient 3. The iris was dysplastic and the posterior fundus
showed large coloboma of the optic nerve, retina, and choroid. Hyaloid vessel proliferation is seen in the vitreous cavity. Panel 6, Mutation
detection of 1190TrC in exon 10 (F258S). d, Fundus photography (panel 1) and fluorescein angiography (panel 2) of the right eye of patient
4, showing ONH. Panel 3, Mutation detection of 1292GrT in exon 10 (S292I). e, The right eye of patient 5 has a slight corneal opacity and
iridocorneal adhesion (panel 1) and deep excavation of the optic-nerve head (3). The left eye has substantial corneal opacity (panel 2). Panel
4, Mutation detection of 1504TrC in exon 12 (S363P). f, The anterior segment (panel 1), fundus photography (panel 2), and fluorescein
angiography (panel 3) of the left eye, with optic-nerve aplasia, of patient 6. The iris was dysplastic, and the optic-nerve head and retinal vessels
were absent, with a remnant of the hyaloid vessels. Panel 4, Mutation detection of 1550ArG in exon 12 (Q378R). g, Fundus photography
(panel 1) and fluorescein angiography (panel 2) of the left eye, with ONH, of patient 7. Panel 3, Mutation analysis identified 1558ArG in
exon 12 (M381V). h, Fundus photography (panel 1) and fluorescein angiography (2) of the left eye, with optic-nerve aplasia, of patient 8. c,
Mutation analysis identified 1588ArG in exon 12 (T391A).
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Figure 2 Effects of PAX6 on PAX2 (a) and of PAX2 on PAX6 (c). CAT activities were measured in P19 cells after cotransfection of
effecter and reporter constructs. Total volume of DNA was adjusted with an empty vector, pBluescript. Cell extracts were prepared after 48 h
and assayed for CAT activities by use of a FAST CAT Green Reagent (Molecular Probes). The CAT activity was quantified by measurement
with a phospho-fluor-imager (Molecular Dynamics) and illustrated in a fold-activation, compared with the condition with the vector alone. The
levels of PAX2 were suppressed with increasing amounts of wild type of PAX6, and vice versa. b, Transactivating potential of PAX6 mutants.
0.1 mg of effecter construct and 1 mg of reporter constructs were cotransfected in P19 cells. Transcription level from P6CON was disturbed
significantly by P68S, Q205X, F258S, and S292I mutants and slightly by S363P, Q378R, M381V, and T391A mutants. d, Effects of PAX6
mutants on PAX2 expression. One mg of effecter construct and 1 mg of reporter constructs were cotransfected in P19 cells. The decreasing level
of PAX6 was significantly disturbed with the P68S, Q205X, S292I, and M381V mutants. Each photograph of CAT assay under the bar graph
is representative of at least three independent experiments.
under the control of sonic hedgehog signaling (Macdon-
ald et al. 1995). Data indicating reciprocal transcriptional
repression of Pax2 and Pax6 also were obtained using
mouse homologues (Schwarz et al. 2000). Thus, al-
though PAX2 and PAX6 were initially considered to be
transcriptional activators, they also may inhibit tran-
scription of some genes to exert their roles during de-
velopment. We next examined the effect of PAX6 and
PAX2 proteins on activities of PAX2 and PAX6 gene
promoters, respectively. A CAT-reporter construct car-
rying an ∼2-kb PAX6 promoter region (the 1285th to
3381st nucleotides in GenBank accession number
U63833), or a 1.2-kb PAX2 promoter region (the
1002nd to 190th nucleotides in GenBank accession
number U45245) was used. When an increasing amount
of the PAX6 or PAX2 expression construct was cotrans-
fected into P19 cells with a constant amount of thePAX2
or PAX6 reporter construct, each CAT activity decreased
in a dose-dependent manner, indicating that PAX6 re-
presses PAX2 gene expression and vice versa (fig. 2a and
2c). By use of this assay system, we evaluated possible
effects of the PAX6 mutations on PAX2 promoter ac-
tivity. Four expression constructs carrying P68S,
Q205X, S292I, or M381V mutations failed to repress
the PAX2 promoter activity, unlike the wild-type PAX6
and other mutant constructs (fig. 2d). These mutations
were found with morning glory disc anomaly or ONH
and caused a functional change in our experimental sys-
tem. Because PAX2 mutations were also found in col-
oboma and ONH (Sanyanusin et al. 1995), we speculate
that failure of the PAX6-PAX2 regulatory circuit may
affect phenotypic manifestations of these anomalies. Ex-
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pression of the CAT-reporter gene was probably inhib-
ited by endogenous PAX6 protein to some extent and
stimulated by Q205X through its dominant-negative ac-
tion on endogenous PAX6, as suggested elsewhere (Singh
et al. 1998). Numerous processes are needed for optic-
nerve formation, so PAX2 and PAX6 may cooperate in
optic-nerve formation or occasionally share tasks; for
example, opening and closing the embryonic fissure
and mutations of either gene cause similar phenotypic
changes.
Our patients had a wide variety of optic-nerve mal-
formations, in which a full series of disease-causing events
of optic-nerve malformation—including embryonic fis-
sure (coloboma), retinal ganglion cells (ONH/aplasia),
and hyaloid vessels (persistent hyperplastic primary vit-
reous)—are included (Brown and Tasman 1983). Because
Pax6/PAX6 is expressed in numerous tissues important
for optic-nerve development—including the CNS, optic
stalk, and retinal progenitors at an early stage, and ret-
inal ganglion cells at a late stage—it is not surprising
that many more variable phenotypes are caused by PAX6
mutations than by PAX2 mutations.
Genetic analysis indicated that haploinsufficiency of the
gene causes the classical aniridia phenotype, in which all
eye tissues are affected. Most mutations detected in an-
iridia result in premature translational termination on one
of the alleles (Martha et al. 1994). In contrast, most
missense mutations generate distinctive nonaniridia phe-
notypes—including anterior segment anomalies, con-
genital cataracts, and foveal hypoplasia—in which cer-
tain eye tissue is affected (Hanson et al. 1999). Because
most of the amino acid residues are conserved, distinct
missense mutations may alter the degree and specificity
of DNA binding and transcriptional regulation by PAX6
protein to a different extent (Yamaguchi et al. 1997;
Azuma et al. 1999). Some missense mutations are
thought to be recurrently associated with a specific phe-
notype in eye anomalies. Two patients with an R128C
mutation, independently identified in Japan and Europe,
had the same phenotype, with foveal hypoplasia (Azuma
et al. 1996; Hanson et al. 1999). Mutations associated
with Peters anomaly were in the N-terminal subdomain
of the PD (van Heyningen and Williamson 2002). In
contrast, a missense mutation in the alternatively spliced
exon was associated with a variety of ocular anomaly
phenotypes (Azuma et al. 1999). No distinct positional
effect of the missense mutations on phenotypic mani-
festation of optic-nerve malformations was found in the
present study. Because the Pax6/PAX6 gene is expressed
repeatedly throughout ocular tissues, these missensemu-
tations probably disturb PAX6 protein function in dif-
ferent ways, which result in various phenotypes.
Besides eye anomalies, patient 3 was mentally retarded,
and patient 4 had an enlarged CNS ventricle and a uri-
nary anomaly. PAX6 plays an important role in CNS
development, and CNS malformation and mental retar-
dation associated with PAX6 mutations have been re-
ported (Malandrini et al. 2001; Sisodiya et al. 2001).
However, gene expression in the urinary tract was not
reported. It is unknown if patient 4 carries compound
mutations of the separate genes related to eye or urinary-
tract development, or whether PAX6 is slightly, or for
a short time, expressed in the urinary tract. BecausePAX2
is expressed in the kidney, extensive analysis of expres-
sion and correlation of PAX6 and PAX2 throughout
development would validate the significance of the genes
in pathogenesis of the diseases in which multiple organs
are involved.
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